Molecular Partners AG Overview
Pro stress-test →Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich developing DARPins, a novel class of potent, specific and versatile small-protein therapies with potential applications in oncology, immuno-oncology, ophthalmology, and infectious diseases. The company has entered several agreements with pharma and biotech companies such as Allergan and Amgen.
Strategic Profile
Pro stress-test →Founded in 2004 by researchers from the University of Zürich who discovered and developed the DARPin technology, the company leverages its proprietary platform for partnered development and internal programs. The company's focus is on advancing its clinical assets, with strong data emerging from MP0533 and MP0712.
Competitive Landscape
Pro stress-test →The company operates in oncology as its main therapeutic focus, competing against established biotech and pharma companies developing protein therapeutics and targeted radiotherapeutics. The DARPin platform's multi-functionality differentiates it in a crowded immuno-oncology and oncology landscape.
Industry Context
Molecular Partners AG operates in Biopharmaceuticals / Oncology / Protein Therapeutics.
Key facts
Founded: 2004 · Headquarters: Zürich, Switzerland